Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate effects on distractor processing in adults with inattention or hyperactivity symptoms
ACTRN12619001752156Phase 4Recruiting
- Sponsor
- Monash University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Monash University. Primary endpoints: Change in response time in the presence of distractors, Change in event-related potentials associated with perceptual decisions and 1 more. Started May 2021; status: recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ACTRN12619001752156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001752156.